Citigroup Cuts Health Catalyst (NASDAQ:HCAT) Price Target to $2.00

Health Catalyst (NASDAQ:HCAT) had its price objective lowered by Citigroup from $2.50 to $2.00 in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other analysts also recently issued reports on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of Health Catalyst in a research report on Monday, May 11th. Wells Fargo & Company upped their price objective on shares of Health Catalyst from $1.00 to $1.75 and gave the stock an “equal weight” rating in a report on Friday, June 26th. Canaccord Genuity Group lifted their price objective on shares of Health Catalyst from $2.00 to $3.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Weiss Ratings raised shares of Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Finally, Stephens decreased their target price on shares of Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Health Catalyst has an average rating of “Hold” and a consensus price target of $2.93.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $1.75 on Tuesday. Health Catalyst has a 1-year low of $0.96 and a 1-year high of $3.80. The firm has a market capitalization of $131.71 million, a P/E ratio of -0.48 and a beta of 1.55. The firm’s 50-day moving average price is $2.00 and its 200-day moving average price is $1.69. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 1.10.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. Health Catalyst had a negative return on equity of 1.57% and a negative net margin of 90.61%.The business had revenue of $70.49 million for the quarter, compared to the consensus estimate of $69.09 million. Equities research analysts anticipate that Health Catalyst will post -0.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC increased its position in shares of Health Catalyst by 816.8% during the 1st quarter. AQR Capital Management LLC now owns 168,344 shares of the company’s stock valued at $763,000 after purchasing an additional 149,981 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock worth $163,000 after purchasing an additional 2,624 shares during the period. Focus Partners Wealth purchased a new position in shares of Health Catalyst in the 1st quarter worth about $46,000. Geode Capital Management LLC boosted its holdings in shares of Health Catalyst by 11.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock worth $6,269,000 after buying an additional 169,580 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Health Catalyst by 13.5% during the second quarter. Rhumbline Advisers now owns 101,986 shares of the company’s stock valued at $384,000 after buying an additional 12,127 shares during the period. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.